S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC
OncLive® On Air - Un pódcast de OncLive® On Air
In this podcast, experts Virginia Kaklamani, MD, DSc, and Tiffany A. Traina, MD, FASCO, discuss the rationale for and data to support combining TROP2-targeting antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) to treat triple-negative breast cancer (TNBC).
